BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

  Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended December 31, 2023, on Wednesday, February 7, 2024.

  February 1, 2024

   · 

  3 min read
• Drug Development

  Purple Biotech Reaches Recommended Phase 2 Dose for NT219

  Purple Biotech Ltd. today announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment of head and neck cancer based on its Phase 1/2 dose escalation study (NCT04474470).

  February 1, 2024

   · 

  8 min read
• Revive Therapeutics Explores the Use of Bucillamine for Long COVID

  Revive Therapeutics Ltd. announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.

  February 1, 2024

   · 

  4 min read
• BioMidwest

  S4 Medical Announces Publication of EASY AF Clinical Study Results Showing Significant Esophageal Injury Reduction in JACC: Electrophysiology

  S4 Medical announced today that its EASY AF FDA study data was published in JACC: Electrophysiology.

  February 1, 2024

   · 

  2 min read
• Business

  Pixelgen Technologies Signs Distribution Agreement in Japan

  Pixelgen Technologies ® announced today that it has signed a non-exclusive agreement with BioStream Co. Ltd of Japan to distribute its groundbreaking spatial proteomics tools for single cells.

  February 1, 2024

   · 

  3 min read
• Genetown

  Data Demonstrating vMap’s Impact on Atrial Fibrillation Treatment Outcomes Unveiled at AF Symposium 2024

  Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, will release findings today at AF Symposium from the recent study Ablation of Non-Pulmonary Vein Atrial Fibrillation Drivers Identified by Machine Learning in Addition to Pulmonary Vein Isolation Improves Procedural Outcomes.

  February 1, 2024

   · 

  3 min read
• Drug Development

  RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

  RS Oncology today announced the successful dosing of the first patient in the Phase 2 dose expansion portion of its United Kingdom multicenter study (MITOPE; NCT05278975 ).

  February 1, 2024

   · 

  3 min read
• Corporate Update on Clinical Evaluation of MedMira’s Products

  MedMira Inc. is pleased to provide an update on the ongoing review process by Health Canada.

  February 1, 2024

   · 

  3 min read
• Business

  Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024

  Organon will release its fourth quarter and full year 2023 financial results on February 15, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.

  February 1, 2024

   · 

  2 min read
• Drug Development

  EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

  EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis.

  February 1, 2024

   · 

  6 min read